戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 able therapeutic strategy for the control of malignant pleural effusion.
2 a to differentially diagnose tuberculous and malignant pleural effusion.
3  talc pleurodesis was successful in treating malignant pleural effusions.
4 ative to conventional inpatient treatment of malignant pleural effusions.
5 n analysis for the differential diagnosis of malignant pleural effusion and benign pleural effusion.
6                          Among patients with malignant pleural effusion and no previous pleurodesis,
7       We recruited lung cancer patients with malignant pleural effusion and patients with nonmalignan
8  from the primary tumor, pleural metastases, malignant pleural effusion, and ascites obtained during
9   These results suggest that drainage of the malignant pleural effusion, and perhaps enzymatic pretre
10 us tissue samples (tumor and normal pleura), malignant pleural effusions, and in established mesothel
11                                              Malignant pleural effusion causes disabling dyspnea in p
12 f tumour volume and metastasis, and in human malignant pleural effusion clinical samples.
13               In cytology-negative suspected malignant pleural effusions, CT-guided pleural biopsy is
14                          Among patients with malignant pleural effusion, daily drainage of pleural fl
15                             With no cure for malignant pleural effusion, efforts are focused on sympt
16 n mice, and we also detected CXCL12-gamma in malignant pleural effusions from patients with breast ca
17                     RATIONALE: Patients with malignant pleural effusions have significant dyspnea and
18 regression analysis revealed that histology, malignant pleural effusion, intraparenchymal liver metas
19 mplement fluid cytology for the diagnosis of malignant pleural effusion is needed.
20                                              Malignant pleural effusion (MPE) confers dismal prognosi
21                                              Malignant pleural effusion (MPE) is challenging to manag
22                                              Malignant pleural effusion (MPE) is indicative of termin
23                                 Diagnosis of malignant pleural effusion (MPE) is made by cytological
24                                              Malignant pleural effusion (MPE) is the lethal consequen
25                                              Malignant pleural effusion (MPE) poses a significant cli
26                                              Malignant pleural effusion (MPE) results from the capaci
27 ficantly prolonged the survival of mice with malignant pleural effusion (MPE), and even achieved comp
28  tuberculous pleural effusion (TPE, n = 50), malignant pleural effusion (MPE, n = 41), other cases in
29                                  Symptomatic malignant pleural effusions (MPE) are treated with chemi
30 s with tuberculous pleural effusion (TPE) or malignant pleural effusions (MPE) frequently have simila
31  Here, we quantified MCs in human and murine malignant pleural effusions (MPEs) and evaluated the fat
32                                              Malignant pleural effusions (MPEs) can be utilized as li
33                             For treatment of malignant pleural effusion, nonsteroidal anti-inflammato
34 y pleural drainage changed the management of malignant pleural effusion, not solely by offering an al
35 table scid mouse xenograft (Sparky-X) from a malignant pleural effusion of a 12-year-old Persian male
36 mechanisms that regulate the pathogenesis of malignant pleural effusion (PE) associated with advanced
37                                          For malignant pleural effusions, pleural fluid cytology is a
38 oduce a similar effect, achieving control of malignant pleural effusion (pleurodesis).
39                              For dyspnea and malignant pleural effusions, providers should offer thor
40  retroviral gene transfer to cancer cells in malignant pleural effusions revealed that transduction w
41 cer cell line (SUM-52PE), originating from a malignant pleural effusion specimen, that can be culture
42 rd, immunoassays and biochemical analyses of malignant pleural effusion specimens revealed CS in rele
43                          Among patients with malignant pleural effusion, thoracoscopic talc poudrage,
44 a known primary malignancy and a symptomatic malignant pleural effusion underwent small-bore-catheter
45  this study was to diagnose lung cancer with malignant pleural effusion using the volatilomic profili
46 neteen consecutive patients with symptomatic malignant pleural effusions were enrolled.
47 s with histocytologically proven symptomatic malignant pleural effusions were included in this phase
48 tients with cytologically negative suspected malignant pleural effusions were recruited.
49 C and talc (1:1) for which 106 patients with malignant pleural effusion who had not previously underg